

	<b>BNT162b2 (%)</b> <b>16-55 years</b> <b>n=2.291/n=2.098</b>	<b>BNT162b2 (%)</b> <b>&gt;55 years</b> <b>n=1.802/n=1.660</b>	<b>Placebo (%)</b> <b>n=4.090</b>	<b>mRNA-1273 (%)</b> <b>16-64 years</b> <b>n=11.406/n=10.985</b>	<b>mRNA-1273 (%)</b> <b>≥65 years</b> <b>n=3.762/n=3.692</b>
<b>Local reactions (7 d after vacc)</b>	dose 1/ dose 2	dose 1/ dose 2	dose 1+2	dose 1/ dose 2	dose 1/ dose 2
Pain	83,1/77,8	71,1/66,1	7,7-14,0	86,9/89,9	74/83,2
Readness	4,5/5,9	4,7/7,2	<1,2	3/8,9	2,3/7,5
Swelling	5,8/6,3	6,5/7,5	<1,2	6,7/12,6	4,4/10,8
<b>Systemic reactions (7 d after vacc)</b>					
Fever (≥38°C)	3,7/5,8	1,4/10,9	0,5-0,9	0,9/17,4	0,3/10,0
Shivering	14,0/35,1	6,3/22,7	3,8-6,4	9,2/48,6	5,4/30,9
Fatigue	47,7/59,4	34,1/50,5	22,8-33,4	38,4/23,0	33,3/24,6
Headache	41,9/51,7	25,2/39,0	24,1-33,7	35,5/62,8	24,5/46,2
Myalgia	21,3/37,3	13,9/28,7	8,2-10,8	23,7/61,6	19,7/47,1
Antipyretic use	27,8/45,0	19,9/37,7	9,8-22,0		
<b>Serious adverse events</b>	<b>n=21.621</b>		n=21.631	n=15.185	
	<b>n(%)</b>		n (%)	n (%)	
SAE	126 (0,6)		111 (0,5)	93 (0,6)	
severe	71 (0,3)		68 (0,3)		
life-threatening	21 (0,1)		23 (0,1)		
vaccine-related	4		0	6 (<0,1)	
anaphylactic events (n)	0		0	1 (<0,1)	

Placebo (%) n=30.323/n=29.243	AZD1222 (%) n=10.069	Controls (%) n=9.902	Johnsson & Johnsson (n/N)	Placebo (n/N)
dose 1+2	dose 1	dose 1		
12,8-18,7	54.2	36.7		
0,4-0,5	14	8.8		
0,3-0,5	10	5.8		
0,2-0,4	7.9	1.2		
4,0-6,4	31.9	8.3		
22,7-28,8	53.1	38.2		
19,3-29,0	52.6	39		
11,8-12,9	44	21.6		
n=15.166	n=12.021	n=11.724		
<b>n(%)</b>				
89 (0,6)	79 (0,7)	89 (0,8)		
4 (<0,1)	3 (<0,1)	3 oder 2 (<0,1)		
1 (<0,1)	1 (<0,1)	0 (<0,1)		